Fast food chains are expanding their retail offerings and seeking viral glory with collectable items, like cups, keychains, ...
Exelixis, Inc. today announced its preliminary unaudited financial results for the fiscal year 2025, provided financial guidance for fiscal year 2026 and delivered an update on its business. Exelixis ...
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million to support Teva’s anti-IL-15 candidate TEV-‘408 TEV- ...
MBX plans to share the full 12-week dataset from Avail and one-year follow-up data at a medical conference in Q2 2026. An FDA End-of-Phase 2 meeting is planned for Q1 2026, as MBX continues to prepare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results